Pharminox Overview

  • Year Founded
  • 2002

Year Founded

  • Status
  • Out of Business

  • Employees
  • 11

Employees

  • Latest Deal Type
  • Out of Business

Pharminox General Information

Description

Developer of small molecule drugs designed to selectively target the telomeres of cancer cells. The company's small molecule drugs help in the treatment of common forms of cancer, with a specific research focus on molecularly targeted DNA damage and inhibition of DNA damage repair mechanisms, enabling physicians to access anti-cancer agents for treatment purpose.

Contact Information

Website
www.pharminox.com
Ownership Status
Out of Business
Financing Status
Formerly VC-backed
Corporate Office
  • BioCity Nottingham
  • Pennyfoot Street
  • Nottingham NG1 1GF
  • England, United Kingdom
+44 01428
Primary Industry
Drug Discovery
Other Industries
Pharmaceuticals
Vertical(s)
Life Sciences, Oncology
Corporate Office
  • BioCity Nottingham
  • Pennyfoot Street
  • Nottingham NG1 1GF
  • England, United Kingdom
+44 01428

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Pharminox Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
6. Out of Business 18-Jul-2017 Completed Out of Business
5. Grant 11-May-2012 Completed Generating Revenue
4. Later Stage VC 08-Jul-2011 Completed Generating Revenue
3. Later Stage VC 30-Jun-2008 Completed Generating Revenue
2. Early Stage VC 29-Jun-2004 $2.74M $3.83M Completed Startup
1. Early Stage VC 17-Jan-2002 $1.08M $1.08M Completed Startup
To view Pharminox’s complete valuation and funding history, request access »

Pharminox Patents

  • 20

    Total Documents Applications and Grants

  • Total Patents Families

  • 3

    Granted

  • Pending

  • Expiring in next 12 mo

Pharminox Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
GB-201205504-D0 Novel anti-proliferative compounds Inactive 28-Mar-2012
GB-201110727-D0 Novel anti-proliferative compounds Inactive 24-Jun-2011
EP-2621929-A1 Novel acridine derivatives Inactive 30-Sep-2010
US-20130310411-A1 Novel acridine derivatives Inactive 30-Sep-2010
GB-201016442-D0 Novel acridine derivatives Inactive 30-Sep-2010 C07D495/04
To view Pharminox’s complete patent history, request access »

Pharminox Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Ready to get started?

Request a free trial

Pharminox FAQs

  • When was Pharminox founded?

    Pharminox was founded in 2002.

  • Where is Pharminox headquartered?

    Pharminox is headquartered in Nottingham, United Kingdom.

  • What is the size of Pharminox?

    Pharminox has 11 total employees.

  • What industry is Pharminox in?

    Pharminox’s primary industry is Drug Discovery.

  • Is Pharminox a private or public company?

    Pharminox is a Private company.

  • What is Pharminox’s current revenue?

    The current revenue for Pharminox is .

  • How much funding has Pharminox raised over time?

    Pharminox has raised $10.2M.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »